14 January 2020
New trials from around the world are affecting the global dermatology market on an almost daily basis, providing patients with new drugs and medical practitioners with more innovative treatment technology than ever before. That’s why Visiongain has made it their business to help inform key stakeholders and business owners about the most current changes and emerging trends.
Here are a few of the most notable highlights in recent months.
Pfizer Shares Results for Janus kinase (JAK1) Inhibitor Therapy
Recently, drug manufacturer Pfizer shared positive results regarding their innovative Janus kinase (JAKI) inhibitor therapy targeted towards those 12 and older. This success now adds to Pfizer’s portfolio of positive Phase III findings by the Food and Drug Administration (FDA) for the treatment of atopic dermatitis.
The clinical trial, a part of the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) global development program, consisted of a 12-week program in which patients were given 100mg or 200mg doses of abrocitinib, or a placebo.
New Findings for Plaque Psoriasis Treatments
Another big breakthrough in the global dermatology market is positive results from patients suffering from plaque psoriasis who have been treated with tildrakizumab-asmn (ILUMYA). Those being treated with ILUMYA showed significant signs of improvement after four years, according to recent data presented in Madrid, Spain, at this year’s annual European Academy of Dermatology and Venereology (EADV) Congress.
The clinical trials compared tildrakizumab with the drug etanercept and a placebo. Each patient was given either a 100 or 200mg dose of tildrakizumab and their progress was assessed during the 200-week trial. Those who received continued therapy reported notable improvement in both their Physician Global Assessment (PGA) scores and PASI. This means progress for treating the severity of plaque psoriasis.
Contact Visiongain for more insight into the global dermatology pipeline
If you want to get a grip on all of the emerging trends in today’s global dermatology market, Visiongain has some insight for you. Our in-depth market reports and forecasts are compiled by industry experts using the most up-to-date primary and secondary sources. This means that you can always count on us to provide you with current market insight and key data required to make the important decisions for the future.
With more than 1,500 reports from over 18 market verticals, Visiongain is sure to have the information you need to solidify your success. Contact us online for more or call +44 (0) 20 7549 9987 today!
The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.
26 November 2020
Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.
26 November 2020
Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.
25 November 2020
Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth